Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune. Read this story
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune. Read this story
More from CNBC | Business Biotechnology Biotech and Pharmaceuticals Pharmaceuticals Health care industry Breaking news Earnings Bristol-Myers Squibb Co Pfizer Inc business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source